Advisory boards bring together a selection of key opinion leaders to discuss a topic important to a life sciences company. Here is how to use engagement technologies to generate actionable insights from your next ad board.
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future.
In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Robin Winter-Sperry and Robert Kersting, PharmD, Global Head, Scientific Alliances, Novartis, about the need for multi-stakeholder partnerships.
In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Jim Wilkinson, PhD, Vice President, Global & US Medical Affairs, Amgen, about how to develop Medical Affairs talent into tomorrow’s leaders.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
The MAPS 2023 Annual Meeting in New Orleans will host a Young Professionals and Future Leaders Reception session on Tuesday March 28. Download the session handout here:
This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
ChatGPT is disrupting content creation, from term papers to journal articles to online information mills and more. This webinar gathers three thought leaders at the cutting edge of this issue to vision how ChatGPT may augment or, at times, undermine the practice of Medical Affairs in areas such as Medical Information, Omnichannel engagement and more.
In today’s episode, we’ll be looking at considerations for Medical Affairs in Rare Disease and Gene Therapy